TSC
EGRX

Two Seas Capital’s Eagle Pharmaceuticals, Inc. EGRX Stock Holding History

Two Seas Capital’s Portfolio EGRX Stock Details EGRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-45,099
Closed -$2.3M – 13
2021
Q4 		$2.3M Buy
+45,099
New +$2.34M 1.76% 8

Other funds holding EGRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BIP
Brandes Investment Partners La Jolla, California $14.1B AUM 25.52% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
Allspring Global Investments
Allspring Global Investments Charlotte, North Carolina $59.7B AUM 29.08% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
SGCIA
Smith Graham & Co Investment Advisors Houston, Texas $868M AUM 24.69% 1-Year Est. Return

Two Seas Capital's EGRX Position: Q1 2022 in Review

Two Seas Capital sold out of Eagle Pharmaceuticals, Inc. (EGRX) in Q1 2022, closing a stake of 45,099 shares — an estimated $2.3M sold.

Two Seas Capital first reported a position in EGRX in Q4 2021 and held it in 1 quarter. The position peaked at $2.3M in Q4 2021. 160 funds tracked by Wall St. Rank hold EGRX as of Q1 2022.

  • Two Seas Capital reported no remaining Eagle Pharmaceuticals, Inc. position as of Q1 2022 after selling out during the quarter.
  • Two Seas Capital sold 45,099 Eagle Pharmaceuticals, Inc. shares in Q1 2022, an estimated $2.3M.
  • Two Seas Capital first reported a position in Eagle Pharmaceuticals, Inc. in Q4 2021 and held it in 1 quarter.
  • Two Seas Capital's Eagle Pharmaceuticals, Inc. position peaked at $2.3M in Q4 2021.
  • 160 funds tracked by Wall St. Rank held Eagle Pharmaceuticals, Inc. as of Q1 2022.

Based on Two Seas Capital's 13F filing for Q1 2022, filed 13 May 2022.